Fermentation Technology-Natural Products Department, Piramal Enterprises Ltd., 1 Nirlon Complex, Off Western Express Highway, Goregaon (East), Mumbai, 400063 India.
School of Bio Sciences and Technology, VIT University, Vellore, 632014 Tamil Nadu India.
Indian J Microbiol. 2015 Jun;55(2):184-93. doi: 10.1007/s12088-014-0506-4. Epub 2014 Oct 31.
Coenzyme Q10 (CoQ10) is a blockbuster nutraceutical molecule which is often used as an oral supplement in the supportive therapy for cardiovascular diseases, cancer and neurodegenerative diseases. It is commercially produced by fermentation process, hence constructing the high yielding CoQ10 producing strains is a pre-requisite for cost effective production. Paracoccus denitrificans ATCC 19367, a biochemically versatile organism was selected to carry out the studies on CoQ10 yield improvement. The wild type strain was subjected to iterative rounds of mutagenesis using gamma rays and NTG, followed by selection on various inhibitors like CoQ10 structural analogues and antibiotics. The screening of mutants were carried out using cane molasses based optimized medium with feeding strategies at shake flask level. In the course of study, the mutant P-87 having marked resistance to gentamicin showed 1.25-fold improvements in specific CoQ10 content which was highest among all tested mutant strains. P-87 was phenotypically differentiated from the wild type strain on the basis of carbohydrate assimilation and FAME profile. Molecular differentiation technique based on AFLP profile showed intra specific polymorphism between wild type strain and P-87. This study demonstrated the beneficial outcome of induced mutations leading to gentamicin resistance for improvement of CoQ10 production in P. denitrificans mutant strain P-87. To investigate the cause of gentamicin resistance, rpIF gene from P-87 and wild type was sequenced. No mutations were detected on the rpIF partial sequence of P-87; hence gentamicin resistance in P-87 could not be conferred with rpIF gene. However, detecting the mutations responsible for gentamicin resistance in P-87 and correlating its role in CoQ10 overproduction is essential. Although only 1.25-fold improvement in specific CoQ10 content was achieved through mutant P-87, this mutant showed very interesting characteristic, differentiating it from its wild type parent strain P. denitrificans ATCC 19367, which are presented in this paper.
辅酶 Q10(CoQ10)是一种重磅营养保健品分子,常用于心血管疾病、癌症和神经退行性疾病的支持性治疗中的口服补充剂。它是通过发酵工艺商业化生产的,因此构建高产 CoQ10 生产菌株是降低成本生产的前提条件。Paracoccus denitrificans ATCC 19367 是一种具有多种生物化学功能的生物体,被选中用于提高 CoQ10 产量的研究。野生型菌株经过伽马射线和 NTG 的反复诱变处理,然后在各种抑制剂(如 CoQ10 结构类似物和抗生素)上进行选择。突变体的筛选是在基于甘蔗蜜的优化培养基中进行的,并在摇瓶水平上采用了补料策略。在研究过程中,对庆大霉素表现出明显抗性的突变体 P-87 的特定 CoQ10 含量提高了 1.25 倍,在所有测试的突变株中最高。P-87 在表型上与野生型菌株在碳水化合物同化和 FAME 图谱上有所不同。基于 AFLP 图谱的分子分化技术显示,野生型菌株和 P-87 之间存在种内多态性。这项研究表明,诱导突变导致庆大霉素抗性有利于提高 P. denitrificans 突变株 P-87 的 CoQ10 产量。为了研究庆大霉素抗性的原因,对 P-87 和野生型的 rpIF 基因进行了测序。在 P-87 的 rpIF 部分序列上未检测到突变;因此,rpIF 基因不能赋予 P-87 庆大霉素抗性。然而,检测导致 P-87 庆大霉素抗性的突变及其在 CoQ10 过量产生中的作用至关重要。尽管通过突变体 P-87 仅实现了特定 CoQ10 含量的 1.25 倍提高,但该突变体表现出非常有趣的特征,与野生型亲本菌株 P. denitrificans ATCC 19367 不同,这在本文中进行了介绍。